ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $614 | $487 | $316 | $216 |
| % Growth | 26.2% | 53.9% | 46.4% | – |
| Cost of Goods Sold | $250 | $182 | $139 | $101 |
| Gross Profit | $364 | $305 | $178 | $116 |
| % Margin | 59.3% | 62.7% | 56.1% | 53.5% |
| R&D Expenses | $45 | $34 | $22 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $250 | $162 | $124 | $84 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $69 | $62 | $67 | $60 |
| Operating Expenses | $364 | $258 | $213 | $155 |
| Operating Income | $1 | $47 | -$35 | -$40 |
| % Margin | 0.1% | 9.6% | -11.2% | -18.4% |
| Other Income/Exp. Net | -$23 | -$27 | -$27 | -$16 |
| Pre-Tax Income | -$22 | $20 | -$63 | -$56 |
| Tax Expense | -$4 | $1 | -$15 | -$13 |
| Net Income | -$19 | $19 | -$48 | -$43 |
| % Margin | -3% | 3.9% | -15.1% | -19.7% |
| EPS | -1.04 | 0.95 | -3.05 | -3.4 |
| % Growth | -209.5% | 131.1% | 10.3% | – |
| EPS Diluted | -1.04 | 0.94 | -3.05 | -3.4 |
| Weighted Avg Shares Out | 19 | 18 | 16 | 13 |
| Weighted Avg Shares Out Dil | 19 | 18 | 16 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18 | $27 | $28 | $12 |
| Depreciation & Amortization | $68 | $60 | $60 | $47 |
| EBITDA | $63 | $107 | $25 | $3 |
| % Margin | 10.3% | 21.9% | 7.9% | 1.4% |